ネクセラファーマの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/03/25 | 1,589 | 1,622 | 1,577 | 1,578 | -12 | -0.8% | 736,100 |
| 2024/03/22 | 1,596 | 1,604 | 1,559 | 1,590 | -4 | -0.3% | 753,600 |
| 2024/03/21 | 1,579 | 1,596 | 1,565 | 1,594 | +53 | +3.4% | 1,286,100 |
| 2024/03/19 | 1,567 | 1,570 | 1,532 | 1,541 | -18 | -1.2% | 608,100 |
| 2024/03/18 | 1,518 | 1,564 | 1,515 | 1,559 | +50 | +3.3% | 1,096,300 |
| 2024/03/15 | 1,525 | 1,537 | 1,483 | 1,509 | -51 | -3.3% | 1,550,700 |
| 2024/03/14 | 1,550 | 1,586 | 1,530 | 1,560 | +3 | +0.2% | 980,200 |
| 2024/03/13 | 1,592 | 1,592 | 1,529 | 1,557 | -25 | -1.6% | 1,615,500 |
| 2024/03/12 | 1,615 | 1,649 | 1,560 | 1,582 | -153 | -8.8% | 5,022,800 |
| 2024/03/11 | 1,770 | 1,780 | 1,707 | 1,735 | -53 | -3% | 1,905,400 |
| 2024/03/08 | 1,671 | 1,826 | 1,664 | 1,788 | +126 | +7.6% | 4,810,300 |
| 2024/03/07 | 1,606 | 1,662 | 1,570 | 1,662 | +65 | +4.1% | 2,001,600 |
| 2024/03/06 | 1,500 | 1,599 | 1,497 | 1,597 | +82 | +5.4% | 2,009,700 |
| 2024/03/05 | 1,469 | 1,546 | 1,457 | 1,515 | +29 | +2% | 1,103,400 |
| 2024/03/04 | 1,535 | 1,540 | 1,484 | 1,486 | -64 | -4.1% | 1,202,800 |
| 2024/03/01 | 1,450 | 1,561 | 1,450 | 1,550 | +94 | +6.5% | 3,123,900 |
| 2024/02/29 | 1,454 | 1,464 | 1,423 | 1,456 | +5 | +0.3% | 749,500 |
| 2024/02/28 | 1,435 | 1,480 | 1,429 | 1,451 | +17 | +1.2% | 1,330,900 |
| 2024/02/27 | 1,424 | 1,434 | 1,388 | 1,434 | +4 | +0.3% | 1,185,400 |
| 2024/02/26 | 1,425 | 1,448 | 1,406 | 1,430 | -3 | -0.2% | 879,200 |
| 2024/02/22 | 1,410 | 1,436 | 1,386 | 1,433 | +14 | +1% | 1,013,500 |
| 2024/02/21 | 1,429 | 1,449 | 1,416 | 1,419 | -20 | -1.4% | 848,200 |
| 2024/02/20 | 1,399 | 1,446 | 1,393 | 1,439 | +57 | +4.1% | 1,799,800 |
| 2024/02/19 | 1,336 | 1,397 | 1,327 | 1,382 | +42 | +3.1% | 1,323,100 |
| 2024/02/16 | 1,332 | 1,344 | 1,313 | 1,340 | +23 | +1.7% | 1,572,400 |
| 2024/02/15 | 1,402 | 1,415 | 1,304 | 1,317 | -80 | -5.7% | 2,397,900 |
| 2024/02/14 | 1,347 | 1,399 | 1,296 | 1,397 | +22 | +1.6% | 3,090,100 |
| 2024/02/13 | 1,385 | 1,410 | 1,363 | 1,375 | -9 | -0.7% | 1,631,800 |
| 2024/02/09 | 1,418 | 1,421 | 1,382 | 1,384 | -49 | -3.4% | 1,577,900 |
| 2024/02/08 | 1,425 | 1,439 | 1,419 | 1,433 | +3 | +0.2% | 831,300 |
| 2024/02/07 | 1,422 | 1,444 | 1,404 | 1,430 | +4 | +0.3% | 1,170,900 |
| 2024/02/06 | 1,405 | 1,431 | 1,388 | 1,426 | +13 | +0.9% | 819,000 |
| 2024/02/05 | 1,406 | 1,419 | 1,388 | 1,413 | +8 | +0.6% | 722,000 |
| 2024/02/02 | 1,421 | 1,435 | 1,401 | 1,405 | -17 | -1.2% | 666,900 |
| 2024/02/01 | 1,428 | 1,435 | 1,395 | 1,422 | -19 | -1.3% | 1,335,600 |
| 2024/01/31 | 1,421 | 1,442 | 1,413 | 1,441 | -3 | -0.2% | 798,500 |
| 2024/01/30 | 1,445 | 1,450 | 1,414 | 1,444 | +2 | +0.1% | 933,100 |
| 2024/01/29 | 1,414 | 1,465 | 1,412 | 1,442 | +22 | +1.5% | 1,047,900 |
| 2024/01/26 | 1,506 | 1,506 | 1,420 | 1,420 | -93 | -6.1% | 2,335,500 |
| 2024/01/25 | 1,458 | 1,513 | 1,448 | 1,513 | +54 | +3.7% | 1,339,900 |
| 2024/01/24 | 1,430 | 1,465 | 1,426 | 1,459 | +26 | +1.8% | 1,009,100 |
| 2024/01/23 | 1,463 | 1,467 | 1,428 | 1,433 | -31 | -2.1% | 752,400 |
| 2024/01/22 | 1,443 | 1,467 | 1,423 | 1,464 | +24 | +1.7% | 758,700 |
| 2024/01/19 | 1,430 | 1,457 | 1,424 | 1,440 | +14 | +1% | 910,900 |
| 2024/01/18 | 1,433 | 1,436 | 1,408 | 1,426 | +4 | +0.3% | 1,093,800 |
| 2024/01/17 | 1,506 | 1,518 | 1,420 | 1,422 | -106 | -6.9% | 2,715,500 |
| 2024/01/16 | 1,530 | 1,533 | 1,506 | 1,528 | ±0 | ±0% | 687,200 |
| 2024/01/15 | 1,540 | 1,549 | 1,515 | 1,528 | -24 | -1.5% | 997,400 |
| 2024/01/12 | 1,599 | 1,623 | 1,548 | 1,552 | -38 | -2.4% | 1,235,700 |
| 2024/01/11 | 1,572 | 1,608 | 1,559 | 1,590 | +30 | +1.9% | 1,609,700 |
301～
350
件表示中 / 5111件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ネクセラファーマ | 92,000円 | +20.3% | - | 0.00% | 163.12倍 | 1.22倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| 杏林製薬 | 148,400円 | -2.4% | -52.3% | 3.84% | 17.76倍 | 0.63倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 栄研化 | 220,000円 | +4.1% | -3.1% | 2.64% | 19.16倍 | 1.67倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ＪＣＲファーマ | 55,400円 | +14.3% | - | 3.61% | 22.50倍 | 1.44倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| あすかＨＤ | 233,000円 | +16.9% | +33.2% | 2.36% | 12.71倍 | 1.01倍 |
|
武田と親密。婦人科領域に強い。先発品比率引き上げに注力。２１年春にあすか製薬が持株会社化 |
市場注目の銘柄
チャート関連のコラム
